Monoclonal antibodies
Monoclonal antibodies are highly homogeneous antibodies produced by a single B-cell clone, directed against a specific antigenic epitope. Their preparation relies on hybridoma technology: immunized mouse B cells are fused with myeloma cells to form hybridoma cells that can proliferate indefinitely and secrete specific antibodies. These antibodies are highly specific and can accurately recognize targets such as viruses and tumor markers, and are widely used in medicine and scientific research. They are used for the targeted treatment of cancer (e.g., trastuzumab), autoimmune diseases (e.g., adalimumab), and infectious diseases (e.g., neocoronazole-neutralizing antibodies) by blocking disease-causing molecules or labeling diseased cells for the immune system to remove. In addition, they are also used in diagnostic reagent development (e.g. ELISA assays) and protein localization analysis in biological research. Compared to polyclonal antibodies, monoclonal antibodies have high batch stability and less cross-reactivity, but are more expensive to develop. In recent years, humanized antibodies modified by genetic engineering have reduced the risk of immune rejection, further promoting their use in precision medicine.
Bioreactor in monoclonal antibodies
Bioreactor is the core equipment for the industrialized production of monoclonal antibodies (mAb), which enables the high-density and high-activity cultivation of antibody-expressing cells (e.g. CHO cells or hybridoma cells) by simulating the cell growth environment.
Cell expansion and expression
- Batch/supplemented culture: Maintain cell metabolic activity, extend the culture cycle (14-21 days), and enhance antibody production (up to 5-10 g/L) by precisely controlling temperature (37°C), pH (6.8-7.4), and dissolved oxygen (30%-60%).
- Perfusion culture: Combined with cell retention technology (hollow fiber membrane or centrifugation), continuous replenishment of fresh medium and removal of metabolic wastes (e.g. lactic acid, ammonia), the cell density can reach >1×10^7 cells/mL, which significantly improves monoclonal antibody yield.
Process control and optimization
- Parameter online monitoring: real-time control of culture environment by DO, pH, CO₂, glucose/lactate sensors, combined with metabolic flux analysis to optimize the replenishment strategy and reduce the accumulation of by-products.
- Automation integration: linkage with PAT (Process Analytical Technology) to automatically adjust stirring rate (50-150 rpm), aeration and nutrient replenishment to ensure batch-to-batch consistency (CV<5%).
Flexibility and Scalability
- Reactor type: from pilot (1-10 L stirred) to production level (2000-20,000 L stainless steel/disposable bioreactors), using the principle of geometric similarity scale-up to keep kLa (oxygen mass transfer coefficient) constant and reduce the risk of process transfer.
Quality control
- Antibody stability assurance: Reduce protein aggregation or degradation through low shear mixing design (e.g., tilted paddles) and precise temperature control (±0.5°C) to ensure homogeneity of antibody glycosylation modifications (key quality attribute CQA).
Integration of Emerging Technologies
- Continuous production process: Tandem connection of multiple bioreactors to realize continuous cell expansion-antibody production and increase production efficiency by 2-3 times.
- Gene editing cell adaptation: optimize reactor feeding strategies (e.g. dynamic glucose replenishment) for CRISPR-optimized high-yield cell lines to break through capacity bottlenecks.
Application Examples
- Clinical grade production: Using 200 L disposable bioreactor, a single batch can produce >1 kg of monoclonal antibody to meet the commercialization demand of PD-1/PD-L1 antibody drugs.
- Personalized therapy: Micro bioreactor (Ambr system) for rapid screening of patient-specific antibody process parameters.
Technological innovations in bioreactors (e.g., AI-driven intelligent regulation, miniaturized high-throughput platforms) are driving monoclonal antibody production toward greater efficiency, lower cost, and greening.